⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INDV News
Indivior PLC Ordinary Shares
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
globenewswire.com
SUPN
INDV
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
globenewswire.com
INDV
Form 8-K
sec.gov
INDV
Indivior to Participate in Upcoming Investor Conferences
globenewswire.com
INDV
Form 8-K
sec.gov
INDV
Indivior Announces $175 Million Accelerated Share Repurchase
globenewswire.com
INDV
Form 8-K
sec.gov
INDV
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
globenewswire.com
INDV
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
globenewswire.com
INDV
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
globenewswire.com
INDV